HDAC1 and neoplasm: These combinations suggest that HDACis can induce glycolytic reprogramming in GBM cells; subsequent glycolytic inhibition compels reliance on fatty acid oxidation (FAO), and dual therapy with romidepsin (HDAC1/2 inhibitor) and etomoxir (FAO inhibitor) has shown impressive tumor suppression in mouse models [298].